Major histocompatibility complex class I antigen presentation pathway protein (MHC-I antigen presentation protein (no widely used single abbreviation for the entire pathway; individual components like HLA-A, TAP1, etc., have their own abbreviations))

The term "靶向肿瘤相关抗原呈递于MHC-I上的靶标蛋白" describes **tumor-associated antigens that are processed inside malignant cells and displayed on the cell surface by major histocompatibility complex class I (MHC-I) molecules**. This process is essential for recognition by cytotoxic CD8+ T lymphocytes during anti-tumor immune responses. The generation and display of these peptides involve several molecular machines collectively known as the **antigen processing and presenting machinery**—including proteasomes/immunoproteasomes that degrade intracellular proteins into peptides; transporter associated with antigen processing 1/2 (**TAP1/TAP2**) which translocate peptides into the endoplasmic reticulum; chaperones like tapasin that assist peptide loading onto nascent HLA class I molecules; and finally assembly with β2-microglobulin before trafficking to the cell surface. Defects in any component can lead to reduced or absent display of tumor-derived peptides on MHC-I molecules—a common mechanism by which cancers evade immune detection. Many modern cancer immunotherapies rely upon intact function of this pathway for efficacy. Thus, while not a single molecular entity but rather a functional category encompassing many possible targets/proteins/peptides within tumors, this system remains central both biologically and therapeutically in oncology research[1][3].

Other names

Tumor-associated antigens presented by MHC class IMHC-I restricted tumor antigensAntigen processing and presenting machinery (APM) proteins

Enhancement of CD8+ T cell recognition of tumor cells via increased peptide-MHC I complex formation; Upregulation of antigen presentation through IFNγ signaling or NLRC5 activation